FDA-approved Skin & aging

Difelikefalin

Difelikefalin is a kappa-opioid agonist peptide. It is filed in this library under skin & aging, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Difelikefalin has an FDA-approved product on the U.S. market, marketed as Korsuva under application NDA214916.

The current label is held by Vifor (International), Inc.

From the FDA label

What Difelikefalin is approved to treat

is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). KORSUVA is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Limitation of Use Korsuva has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Difelikefalin, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on skin & aging

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Difelikefalin. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides